Suppression of mammary gland carcinogenesis by post-initiation treatment of rats with tamoxifen or indole-3-carbinol or their combination

European Journal of Cancer Prevention

Volumn 16, Issue 2, 2007, Pages 130-141

  Malejka Giganti, Danuta ^a,b,c   Parkin, Daniel R ^a   Bennett, Kristen K ^a   Lu, Yongjian ^b   Decker, Richard W ^b   Niehans, Gloria A ^a,b   Bliss, Robin L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anticarcinogenic agents; Chemoprevention; Indole 3 carbinol; Rat mammary tumors; Tamoxifen

Indexed keywords

3 INDOLEMETHANOL; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CYTOCHROME P450; DIMETHYLBENZ[A]ANTHRACENE; ESTRONE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BREAST CARCINOGENESIS; CANCER INHIBITION; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; FEEDING; FEMALE; LIVER WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TUMOR VOLUME; UTERUS WEIGHT;

ANIMALS; ANTICARCINOGENIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; INDOLES; MAMMARY NEOPLASMS, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 33847006976     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000228401.14988.50     Document Type: Article

References (44)

1. Agresti A (1990). Categorical data analysis. New York: Wiley. pp. 306-346.
2. Ashkenazi A, Dixit VM (1998). Death receptors: signaling and modulation. Science 281:1305-1308.
3. Ashok BT, Chen Y, Liu X, Bradlow HL, Mittelman A, Tiwari RK (2001). Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol. Nutr Cancer 41:180-187.
4. Ashok BT, Chen YG, Liu X, Garikapaty VP, Seplowitz R, Tschorn J, et al. (2002). Multiple molecular targets of indole-3-carbinol, a chemopreventive antiestrogen in breast cancer. Eur J Cancer Prev 11 (Suppl 2):S86-S93.
5. Bergh J (2003). Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen? Lancet 362:183-184.
6. Chen M, Wang J (2002). Initiator caspases in apoptosis signaling pathways. Apoptosis 7:313-319.
7. Christov K, Ikui A, Shilkaitis A, Green A, Yao R, You M, et al. (2003). Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat 77:253-264.
8. Constantinou AI, White BE, Tonetti D, Yang Y, Liang W, Li W, et al. (2005). The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer 41:647-654.
9. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, et al. (1998). Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273:3838-3847.
10. Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, et al. (1999). Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59:1244-1251.
11. Cram EJ, Liu BD, Bjeldanes LF, Firestone GL (2001). Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem 276:22332-22340.
12. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300.
13. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. (2003). A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790.
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
15. Gao X, Petroff BK, Oluola O, Georg G, Terranova PF, Rozman KK (2002). Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation. Toxicol Appl Pharmacol 183:179-188.
16. Ge X, Fares FA, Yannai S (1999). Induction of apoptosis in MCF-7 cells by indole-3-carbinol is independent of p53 and bax. Anticancer Res 19:3199-3203.
17. Green DR (1998). Apoptotic pathways: the roads to ruin. Cell 94:695-698.
18. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, et al. (1995). Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15:709-716.
19. Heffelfinger SC, Gear RB, Schneider J, LaDow K, Yan M, Lu F, et al. (2003). TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen. Lab Invest 83:1001-1011.
20. Horn TL, Reichert MA, Bliss RL, Malejka-Giganti D (2002). Modulations of P450 mRNA in liver and mammary gland and P450 activities and metabolism of estrogen in liver by treatment of rats with indole-3-carbinol. Biochem Pharmacol 64:393-404.
21. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL (1993). Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45:1129-1136.
22. Kossoy G, Yarden G, Ben-Hur H, Kossoy N, Stark A, Madar Z, et al. (2001). Comparative effects of dimethylbenz(a)anthracene and a 15% olive-oil diet on cellular components and expression of apoptosis-related proteins in the spleen and mammary gland tumors of rats. Oncol Rep 8:435-439.
23. Kupfer D, Dehal SS (1996). Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase. Methods Enzymol 272:152-163.
24. Le CT (1997). Applied survival analysis. New York: Wiley.
25. Malejka-Giganti D, Niehans GA, Reichert MA, Bliss RL (2000). Post-initiation treatment of rats with indole-3-carbinol or β- naphthoflavone does not suppress 7,12-dimethylbenz[a]anthracene-induced mammary gland carcinogenesis. Cancer Lett 160:209-218.
26. Malejka-Giganti D, Bennett KK, Culp SJ, Beland FA, Shinozuka H, Bliss RL (2005). Suppression of 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis by pre-initiation treatment of rats with β-naphthoflavone coincides with decreased levels of the carcinogen-derived DNA adducts in the mammary gland. Cancer Detect Prev 29:338-347.
27. Mandlekar S, Hebbar V, Christov K, Kong AN (2000). Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 60:6601-6606.
28. McDougal A, Wormke M, Calvin J, Safe S (2001). Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res 61:3902-3907.
29. Nunez G, Benedict MA, Hu Y, Inohara N (1998). Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237-3245.
30. Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC, Pitot HC (1995). Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res 55:1780-1786.
31. Parkin DR, Malejka-Giganti D (2004). Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect Prev 28:72-79.
32. Quinn GP, Keough MJ (2002). Experimental design and data analysis for biologists. Cambridge: Cambridge University Press.
33. Rahman KM, Aranha O, Glazyrin A, Chinni SR, Sarkar FH (2000). Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 19:5764-5771.
34. Ritter CL, Prigge WF, Reichert MA, Malejka-Giganti D (2001). Oxidations of 17β-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or β-naphthoflavone. Can J Physiol Pharmacol 79:519-532.
35. Stoner G, Casto B, Ralston S, Roebuck B, Pereira C, Bailey G (2002). Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol. Carcinogenesis 23:265-272.
36. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM (1999). Distinct caspase cascades are initiated in receptor-mediated and chemicalinduced apoptosis. J Biol Chem 274:5053-5060.
37. Suzuki S, Kitamura S, Sakamoto S, Sassa S, Mitamura T, Kudo H, et al. (1998). Effects of tamoxifen on mammary tumors and bone in 7,12-dimethylbenz-(a)anthracene-treated rats. Anticancer Res 18:871-876.
38. Telang NT, Katdare M, Bradlow HL, Osborne MP, Fishman J (1997). Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med 216:246-252.
39. Verhoeven DT, Verhagen H, Goldbohm RA, van den Brandt PA, van Poppel G (1997). A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Chem Biol Interact 103:79-129.
40. Wakeling AE (1995). Tissue-specific actions of antioestrogens. Mutat Res 333:45-49.
41. Wattenberg LW, Loub WD (1978). Inhibition of polycyclic aromatic hydrocarboninduced neoplasia by naturally occurring indoles. Cancer Res 38: 1410-1413.
42. White IN, Davies A, Smith LL, Dawson S, De Matteis F (1993). Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem Pharmacol 45:21-30.
43. Zhang X, Malejka-Giganti D (2003). Effects of treatment of rats with indole-3-carbinol on apoptosis in the mammary gland and mammary adenocarcinomas. Anticancer Res 23:2473-2480.
44. Zimniski SJ, Warren RC (1993). Induction of tamoxifen-dependent rat mammary tumors. Cancer Res 53:2937-2939.